Newspaper publication of Q2 FY27 standalone results
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Par Drugs published unaudited standalone results for the quarter and half-year ended 30 September 2026. Q2 operating income was Rs 2,743.19 lakh, down from Rs 2,865.89 lakh a year earlier. Profit after tax fell to Rs 262.80 lakh from Rs 412.96 lakh, and EPS declined to Rs 2.14 from Rs 3.36. Half-year operating income rose 7.3% to Rs 5,871.24 lakh, but profit after tax edged down 1.6% to Rs 734.07 lakh.
Q2 profit fell much faster than revenue, indicating weaker margins and possible near-term pressure on the stock.